4 ms·

This is a great idea. Since this technology has been available since the 80s according to the article, why isn’t this already the default way of producing drugs

This is a great idea. Since this technology has been available since the 80s according to the article, why isn’t this already the default way of producing drugs? Why do companies rely on fragile long term supply chains instead of a scalable faster process under their control? In other words there must be some reason the market hasn’t adopted this - what is it?

vikramkr 6y ago
They tried with artemisinin and it was a very notable failure. The science worked but the economics didn't add up. The main reason is because chemical drugs are pretty easy to synthesize (even from plants) and that synthetic bio doesnt give you any advantage over traditional methods- if anything you get lower throughput. You cant solve a human supply chain problem with new technology if the same humans are making the same decisions about their operations. Synbio has been overhyped to hell and back as a silver bullet. Tech VCs have eaten it up and donated hundreds of millions of dollars to the cause because the biologists running these companies have gone out of their way to convince people that they can program biology like computers, whatever that means.the big synbio drug manufacturing company is gone, the big biofuel companies are gone, that's hundreds of millions of dollars from the market trying to adopt this. I'm saying all this as the founder of a synbio company by the way- in the past few years we've finally started coming down the hype curve with Joule's implosion and it's wonderful. 10 million dollars invested in promising new approaches and markets will help the field out a lot more than 100 million invested in an overhyped company blowing it all on rent in cambridge and promising to produce more fuel per acre than physically possible with the amount of sunlight available.
- martythemaniak 6y ago
  What really happened with Joule? I remember reading about it in Church's book, but nothing outside that.
  - vikramkr 6y ago
    They couldn't deliver on their promises and got tangled up in the 2016 Hillary email/podesta/Russia debacle as well as the Volkswagen diesel scandal and imploded soon after. They just couldn't compete with cheap gasoline, and their claims about how much they could produce per acre of land were dubious . https://www.biofuelsdigest.com/bdigest/2017/07/18/heat-death-joule-unlimited-collapses-as-oil-prices-fall-time-passes-pressure-mounts/ https://www.biofuelsdigest.com/bdigest/2017/07/18/heat-death... https://www.bostonglobe.com/business/2017/09/01/how-biofuel-dream-turned-into-nightmare/rt5ve7mE4YUZUOrqdaTqWK/story.html?outputType=amp https://www.bostonglobe.com/business/2017/09/01/how-biofuel-...
pharke 6y ago
From my perspective of paying attention to some of the articles that have been coming out over the years and reading into the science a bit, one of the big factors seems to be identifying all of the genes necessary for supporting the pathway that synthesizes these compounds. If you are only producing a single protein that is coded for by a stretch of DNA it is fairly straightforward to insert that into bacteria. If what you want to do involves multiple steps carried out by enzymes to transform one molecule into another then you have quite a different challenge. It's the difference between extraction of raw materials vs. building a supply chain that takes those raw materials and refines them and combines them into finished goods.
- toufka 6y ago
  This is a good assessment. And Dr. Smolke (the author) is actually at the very forefront of combining and mixing up many pathways in one system to create a new compound. Her skill at engineering multiple pathways at the same time is at the edge of the state of the art. So that can be taken two ways - either she's one of very few who can do it, so she's overconfident in how well others can follow. Or, she is uniquely aware of the challenges yet sees a path through them heading into the future.
hobofan 6y ago
There are many reasons why it's not as easy as the article lays it out: - Especially for drugs, if they interact with core mechanisms that are common to many eukaryotes, they might interact with the yeast itself, and possibly inhibit their growth too much - If you know a organism that produces your desired product, you first have to discover the pathway it uses to produce it. This includes discovering all of the proteins involved in the pathway, which isn't always straightforward. - If you can't construct a pathway from existing proteins, things will become a lot harder as you now also have to design a new protein to do the job. Our ability to do that is still quite limited (as it's somewhat blocked on protein folding prediction like many things in biotech).

vikramkr 6y ago

They tried with artemisinin and it was a very notable failure. The science worked but the economics didn't add up. The main reason is because chemical drugs are pretty easy to synthesize (even from plants) and that synthetic bio doesnt give you any advantage over traditional methods- if anything you get lower throughput. You cant solve a human supply chain problem with new technology if the same humans are making the same decisions about their operations. Synbio has been overhyped to hell and back as a silver bullet. Tech VCs have eaten it up and donated hundreds of millions of dollars to the cause because the biologists running these companies have gone out of their way to convince people that they can program biology like computers, whatever that means.the big synbio drug manufacturing company is gone, the big biofuel companies are gone, that's hundreds of millions of dollars from the market trying to adopt this. I'm saying all this as the founder of a synbio company by the way- in the past few years we've finally started coming down the hype curve with Joule's implosion and it's wonderful. 10 million dollars invested in promising new approaches and markets will help the field out a lot more than 100 million invested in an overhyped company blowing it all on rent in cambridge and promising to produce more fuel per acre than physically possible with the amount of sunlight available.

martythemaniak 6y ago
What really happened with Joule? I remember reading about it in Church's book, but nothing outside that.
- vikramkr 6y ago
  They couldn't deliver on their promises and got tangled up in the 2016 Hillary email/podesta/Russia debacle as well as the Volkswagen diesel scandal and imploded soon after. They just couldn't compete with cheap gasoline, and their claims about how much they could produce per acre of land were dubious . https://www.biofuelsdigest.com/bdigest/2017/07/18/heat-death-joule-unlimited-collapses-as-oil-prices-fall-time-passes-pressure-mounts/ https://www.biofuelsdigest.com/bdigest/2017/07/18/heat-death... https://www.bostonglobe.com/business/2017/09/01/how-biofuel-dream-turned-into-nightmare/rt5ve7mE4YUZUOrqdaTqWK/story.html?outputType=amp https://www.bostonglobe.com/business/2017/09/01/how-biofuel-...

pharke 6y ago

From my perspective of paying attention to some of the articles that have been coming out over the years and reading into the science a bit, one of the big factors seems to be identifying all of the genes necessary for supporting the pathway that synthesizes these compounds. If you are only producing a single protein that is coded for by a stretch of DNA it is fairly straightforward to insert that into bacteria. If what you want to do involves multiple steps carried out by enzymes to transform one molecule into another then you have quite a different challenge. It's the difference between extraction of raw materials vs. building a supply chain that takes those raw materials and refines them and combines them into finished goods.

toufka 6y ago
This is a good assessment. And Dr. Smolke (the author) is actually at the very forefront of combining and mixing up many pathways in one system to create a new compound. Her skill at engineering multiple pathways at the same time is at the edge of the state of the art. So that can be taken two ways - either she's one of very few who can do it, so she's overconfident in how well others can follow. Or, she is uniquely aware of the challenges yet sees a path through them heading into the future.

hobofan 6y ago

There are many reasons why it's not as easy as the article lays it out: - Especially for drugs, if they interact with core mechanisms that are common to many eukaryotes, they might interact with the yeast itself, and possibly inhibit their growth too much - If you know a organism that produces your desired product, you first have to discover the pathway it uses to produce it. This includes discovering all of the proteins involved in the pathway, which isn't always straightforward. - If you can't construct a pathway from existing proteins, things will become a lot harder as you now also have to design a new protein to do the job. Our ability to do that is still quite limited (as it's somewhat blocked on protein folding prediction like many things in biotech).